Author: Verismo Therapeutics

Verismo Therapeutics Presents Preclinical Data at SITC 2026 Demonstrating Enhanced Tumor Control and Reduced Cytokine Release with SynKIR™-110 KIR-CAR Compared to Conventional CAR T

November 3, 2026
Verismo Therapeutics Expands KIR-CAR Solid Tumor Treatment Pipeline with Novel Binder Developed at Penn Targeting Claudin 6 (CLDN6)

July 21, 2026

Verismo Therapeutics Presents Preclinical Data at SITC 2026 Demonstrating Enhanced Tumor Control and Reduced Cytokine Release with SynKIR™-110 KIR-CAR Compared to Conventional CAR T